Literature DB >> 30412428

Use of gadolinium contrast agents in paediatric population: Donald Rumsfeld meets Hippocrates!

Ruchir Shah1, Felice D'Arco2, Bruno Soares3, Jessica Cooper2, Joe Brierley2.   

Abstract

Gadolinium is a contrast agent that is used in MRI. There is new evidence that gadolinium accumulates in a patient's body and the effects of this accumulation is unknown. This has resulted in different advice being given by European Medicine Agency and U.S. Food and Drug Administration. The European Medicine Agency recommended stopping the use of linear Gadolinium agents (requiring more proof of safety) while the Food and Drug Administration continues to permit its use (requiring more proof of harm). Gadolinium should be used if deemed clinically necessary. Children and parents should be informed of the benefits and potential harm of using gadolinium-based contrast. It is up for debate whether those imaged before with gadolinium will benefit from being informed of new evidence.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30412428      PMCID: PMC6404820          DOI: 10.1259/bjr.20180746

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  2 in total

1.  Noncontrast MRI Protocol for Selected Pediatric Pituitary Endocrinopathies: A Procedure with High Diagnostic Yield and Potential to Reduce Anesthesia and Gadolinium-Based Contrast Exposure.

Authors:  J Huang; A Sarma; N Gupta; S Little; S Pruthi
Journal:  AJNR Am J Neuroradiol       Date:  2021-09-02       Impact factor: 4.966

Review 2.  An Update on Childhood-Onset Takayasu Arteritis.

Authors:  Florence A Aeschlimann; Rae S M Yeung; Ronald M Laxer
Journal:  Front Pediatr       Date:  2022-04-13       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.